Remigromig met the non-inferiority endpoint vs ranibizumab in the BRUNELLO DME trial, but PDR adverse events were higher.
Bristol Myers Squibb's admilparant met the Phase III ALOFT-IPF primary endpoint, showing significant FVC gains in pulmonary ...
Icotrokinra (Icotyde) sustained PASI 90 in at least 72% of plaque psoriasis patients through two years in Phase III ICONIC-LEAD. Read the full results.
EU application is back under EMA review for EGFR-mutated NSCLC. Find out what this resubmission means for patients today.
FDA approves Hovilpri (pritelivir) for herpes lesions resistant to acyclovir, valacyclovir, or famciclovir in ...
A JAMA Phase III trial finds nicotinamide riboside worsens outcomes vs placebo in early Parkinson's. Read the full NOPARK ...
FDA approves Teva's Weltruza, the first once-monthly subcutaneous olanzapine LAI for adult schizophrenia. Read what it means ...
Chai Discovery and GSK announce a collaboration giving GSK access to protein folding and design AI models after wet-lab ...
Ultragenyx agreed to sell a rare pediatric disease priority review voucher for $210 million after GENGLYCOS approval. Explore ...
EPI-321 data show increased lean muscle volume and strength after six months in six people with FSHD. Read the full Phase I/II study results and updates.
RougeTx raised $58 million in Series A funding to advance its HHT treatment toward clinical development. See who backed the ...
A Dutch court barred Merck from making or selling Keytruda SC in eight European markets, ruling in Halozyme’s patent dispute. Read what the order means now.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results